<DOC>
	<DOC>NCT01541670</DOC>
	<brief_summary>The purpose of this study is to determine the safety and tolerability of Anti-MIF Antibody in subjects with lupus nephritis.</brief_summary>
	<brief_title>Safety Study of Anti-Macrophage Migration Inhibitory Factor (Anti-MIF) Antibody in Lupus Nephritis</brief_title>
	<detailed_description />
	<mesh_term>Lupus Erythematosus, Systemic</mesh_term>
	<mesh_term>Nephritis</mesh_term>
	<mesh_term>Lupus Nephritis</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<criteria>Signed and dated written informed consent obtained from the subject Males and females of age 18 years and older at the time of screening Established diagnosis of systemic lupus erythematosus (SLE) according to the American College of Rheumatology classification criteria Documented renal biopsy evidence of proliferative glomerulonephritis prior to screening Urine proteintocreatinine ratio &gt; 0.5 (mg/mg) Any significant health problem other than lupus or lupus nephritis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2015</verification_date>
</DOC>